Melinta Therapeutics, Inc. (NASDAQ:MLNT) has been given an average recommendation of “Hold” by the sixteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.88.
A number of analysts have recently commented on the company. Jefferies Group reissued a “hold” rating and issued a $3.00 price objective on shares of Melinta Therapeutics in a research note on Thursday, September 14th. ValuEngine upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Zacks Investment Research downgraded Melinta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Gabelli upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Finally, Ladenburg Thalmann Financial Services upgraded Melinta Therapeutics from a “neutral” rating to a “buy” rating in a research note on Thursday, November 30th.
Shares of Melinta Therapeutics (MLNT) opened at $16.50 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.49 and a current ratio of 11.49. The firm has a market capitalization of $167.70, a price-to-earnings ratio of -2.25 and a beta of 1.16. Melinta Therapeutics has a 12 month low of $10.25 and a 12 month high of $31.70.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/25/melinta-therapeutics-inc-mlnt-given-average-recommendation-of-hold-by-brokerages.html.
About Melinta Therapeutics
Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.